Payment overview · 2025
General Payments
$148.18
9 reported records · 7 companies
Healthcare provider profile · identity verified
Curtis Brian Williams, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OKLAHOMA CITY, OK · NPI 1487658449
Verified facts
What the public records show
CMS Open Payments records show Curtis Brian Williams, MD received $148.18 in general payments during 2025 across 9 reported records.
Sumitomo Pharma America, Inc. accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $38.34 | 25.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.50 | 19.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.57 | 13.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.19 | 11.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.02 | 10.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.01 | 10.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.55 | 9.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $148.18 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $38.34 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.50 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 475 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 434 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 371 | 104 |
| Metformin Hcl | Metformin Hcl | 266 | 79 |
| Omeprazole | Omeprazole | 233 | 65 |
| Gabapentin | Gabapentin | 218 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 211 | 57 |
| Prednisone | Prednisone | 201 | 138 |
| Losartan Potassium | Losartan Potassium | 185 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 161 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 42 |
| Lisinopril | Lisinopril | 152 | 46 |
| Potassium Chloride | Potassium Chloride | 151 | 51 |
| Simvastatin | Simvastatin | 151 | 45 |
| Furosemide | Furosemide | 145 | 52 |
| Montelukast Sodium | Montelukast Sodium | 144 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 38 |
| Allopurinol | Allopurinol | 130 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 43 |
| Carvedilol | Carvedilol | 116 | 28 |
| Azithromycin | Azithromycin | 101 | 87 |
| Trulicity | Dulaglutide | 91 | 14 |
| Atenolol | Atenolol | 89 | 22 |
| Eliquis | Apixaban | 84 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 22 |
| Tramadol Hcl | Tramadol Hcl | 79 | 21 |
| Ozempic | Semaglutide | 75 | 15 |
| Meloxicam | Meloxicam | 71 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 21 |
| Jardiance | Empagliflozin | 69 | 17 |
| Finasteride | Finasteride | 66 | 17 |
| Famotidine | Famotidine | 65 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 12 |
| Sertraline Hcl | Sertraline Hcl | 58 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | 13 |
| Pregabalin | Pregabalin | 55 | 21 |
| Glipizide | Glipizide | 52 | 15 |
| Alendronate Sodium | Alendronate Sodium | 51 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Glimepiride | Glimepiride | 50 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 13 |
| Myrbetriq | Mirabegron | 49 | 12 |
| Celecoxib | Celecoxib | 48 | 17 |
| Synthroid | Levothyroxine Sodium | 48 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 36 |
| Alprazolam | Alprazolam | 43 | 13 |
| Lovastatin | Lovastatin | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | 12 |
| Spironolactone | Spironolactone | 38 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Cephalexin | Cephalexin | 33 | 28 |
| Ketoconazole | Ketoconazole | 33 | 16 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | 11 |
| Lorazepam | Lorazepam | 29 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | 20 |
| Estradiol | Estradiol | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 12 |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 15 |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Victoza 3-Pak | Liraglutide | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $148.18 · 9 records | Sumitomo Pharma America, Inc. | BREZTRI, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, GEMTESA, NURTEC ODT, OTEZLA, REPATHA, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error